Recent Investment Analysts’ Ratings Updates for Septerna (SEPN)

Septerna (NASDAQ: SEPN) recently received a number of ratings updates from brokerages and research firms:

• 11/19/2024 – Septerna is now covered by analysts at JPMorgan Chase & Co.. They set an “overweight” rating and a $38.00 price target on the stock.
• 11/19/2024 – Septerna is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $43.00 price target on the stock.
• 11/19/2024 – Septerna is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $50.00 price target on the stock.
• 11/19/2024 – Septerna is now covered by analysts at TD Cowen. They set a “buy” rating on the stock.

Septerna Price Performance

Shares of SEPN opened at $24.78 on Thursday. Septerna, Inc. has a 1-year low of $18.62 and a 1-year high of $26.34.

Insider Activity at Septerna

In other news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the company’s stock in a transaction on Monday, October 28th. The stock was bought at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the transaction, the insider now directly owns 6,215,591 shares in the company, valued at $111,880,638. The trade was a 6.34 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.